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ABSTRACT 
Investigation of Magnetic Resonance Imaging and Spectroscopy for the Detection of 
Breast Cancer 
by 
Robert Thomas Etnire 
Dr. Phillip W. Patton, Examination Committee Chair 
Associate Professor of Health Physics 
University of Nevada, Las Vegas 
Magnetic resonance imaging (MRI) of the breast offers an alternative to screening 
mammography which may benefit those women at high risk for breast cancer, women 
under the age of 40, and those with dense breast tissue. One concern with MRI is the 
number of high false positives. Coupling MRI with magnetic resonance spectroscopy 
(MRS) may lower the number of false positives, and thus improve the diagnostic 
capabilities of MRI for the clinician. MRS for breast imaging focuses on the total choline 
containing compounds in the spectra in the suspected breast lesion to analyze areas of 
concern. The results of the study indicate that MRI helps differentiate potential lesions in 
the breast from healthy tissue, which is clearly seen in scans containing contrast. Also, 
MRS helped to confirm if a lesion is malignant by determining the SNR of the lesions, 
with an SNR of greater than or equal to 2.0 indicating malignancy. 
Keywords; magnetic resonance imaging, magnetic resonance spectroscopy, breast, 
mammography 
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CHAPTER 1 
INTRODUCTION 
Effectively treating breast cancer continues to be an extremely difficult task. Imaging 
modalities and radiation therapy work jointly in order to accurately locate and then 
effectively treat tumors. While current therapies can be effective, they generally are 
unsuccessful in changing prognosis in the more common cancers (Allen et al. 2001). The 
clinical and pathological findings and the type of treatment to be performed varies with 
each individual patient. The effectiveness of different imaging modalities in detailing the 
various breast regions impacts the diagnosis and subsequent treatment options. 
The American Cancer Society has issued new recommendations for women at 
different levels of risk of breast cancer (Saslow et al. 2007). The recommendations for 
the use of screening MRI is for those women with approximately 20-25% or greater 
increased lifetime risk of developing a form of breast cancer. This includes women with 
a family history of breast or ovarian cancer and women who have received previous 
treatment with chest irradiation, such as for Hodgkin's disease. In addition, a recent 
study found that MRI can detect cancer in the contralateral breast that may be missed by 
mammography, further enhancing the need for MRI (Lehman et al. 2007). 
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Anatomy of the Breast 
The breasts rest on the pectoralis major, the chest muscle that covers the ribs. They 
are supported by and attached to the front of the chest wall on both sides of the sternum 
by ligaments (National Cancer Institute 2006). Even though the breasts sit on a major 
chest muscle, it has no muscle tissue itself. It is made up of a layer of fat that surrounds 
the glands and extends throughout the breast. Each breast is made up of approximately 
15-20 lobes (National Cancer Institute 2007a). The lobes are made up of several smaller 
lobules. At the end of the lobules, there are tiny bulb-like glands where the milk is 
produced (National Cancer Institute 2006). The milk flows from the lobules through the 
ducts to the nipple. The fat that covers the lobes is what gives the breast its size and 
shape. Figure 1 details the anatomy of the breast. 
Nipple surface 
Areola 
Fatty tissue 
Figure 1. Detailed anatomy of the breast (National Cancer Institute 2006). 
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The breasts also contain lymph vessels which lead to the lymph nodes (National 
Cancer Institute 2007a). There are groups of lymph nodes located near the breast in the 
axilla, above the collarbone, behind the sternum, and other various locations throughout 
the body. Figure 2 illustrates the locations of lymph nodes in and surrounding the 
breasts. Breast tissue and breast cancer both appear bright when using mammography, 
which is part of the problem in detecting breast cancer using screening mammography. 
Lobules 
Lobe 
Ducts 
" Nipple " 
Areola 
Fat 
Lympli 
n o d e s
 Lymph 
vessels 
Figure 2. Lymph nodes in and surrounding the breast (National Cancer Institute 2007a). 
Breast Cancer Statistics 
The main locations of breast cancer include the breast or chest wall, the axilla, and 
the ipsilateral supraclavicular and internal mammary lymph nodes. Breast cancer 
typically starts in the ducts and then spreads to the lobules and lobes, and finally to the 
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lymph nodes. The number of breast cancer incidences from 2000-2003 was 199,479 for 
invasive cases and 44,913 for in situ cases (National Cancer Institute 2007b). Table 1 
details the number of incidences by age and type. Using the previous data for 2005, the 
American Cancer Society estimated 211,240 new cases of invasive breast cancer would 
be diagnosed as well as 58,490 new cases of in situ breast cancer among women per year 
(American Cancer Society 2005). As a result of these case estimates, the American 
Cancer Society estimated 40,410 deaths from breast cancer yearly. Table 2 details the 
estimated number of new breast cancer cases and deaths in women by age for 2005. 
The incomplete killing of malignant cancer cells that have spread throughout the body 
is a major failing in the management of breast cancer (Allen et al. 2003). There are 
several different options available for the treatment of breast cancer, such as 
chemotherapy, surgery, radiation therapy, and hormone therapy. Because of the different 
treatment options and the ongoing increase in breast cancer cases each year, an effective 
no/minimal risk imaging modality is needed in order to clearly identify tumors in and 
around the breast, so an effective treatment process can be implemented. 
Table 1. Age Distribution (%) of breast cancer cases by site for all races, 2000-2003 
(National Cancer Institute, 2007b). 
Site 
Invasive 
In situ 
<20 
0.0 
0.0 
20-34 
1.9 
0.8 
35-44 
10.6 
11.5 
45-54 
22.1 
27.6 
55-64 
22.8 
25.0 
Age 
65-74 
20.4 
20.3 
75-84 
16.8 
12.5 
>85 
5.4 
2.2 
All Ages 
100.0 
100.0 
Cases 
199,479 
44,913 
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Table 2. Estimated new breast cancer cases and 
deaths in women by age in the United States, 2005 
(American Cancer Society 2006). 
Age 
Under 40 
40 and older 
Under 50 
50 and older 
Under 65 
65 and older 
All ages 
In situ 
cases 
1600 
56890 
13760 
44730 
37040 
21450 
58490 
Invasive 
cases 
9510 
201730 
45780 
165460 
123070 
88170 
211240 
Deaths 
1110 
39300 
5590 
34820 
17470 
22940 
40410 
Breast cancer screening has been recommended for several decades and the majority 
of women over the age of 40 in the United States participate in screening activities 
(Elmore et al. 2005). There are rationales behind screening for a disease before it 
becomes clinically evident. They are primarily based on the principle that early 
detection allows for intervention that interrupts the natural history of the disease and 
prevents a detrimental outcome (Lee et al. 2004). The ideal screening test should be 
noninvasive or minimally invasive, be relatively inexpensive, and have both a low false-
negative rate and low false-positive rate. In summary, the screening should produce 
more benefit than harm and do so at a cost that is affordable. 
Imaging Modalities for the Detection of Breast Cancer 
The primary imaging modality used to detect clinically occult breast cancer is 
mammography (Bluemke et al. 2004). However, due to the similarities of breast tissue 
and microcalcifications, mammography has limitations in both sensitivity and specificity 
which has led to the exploration of other imaging techniques. One of the most promising 
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substitutions for mammography is magnetic resonance imaging (MRI), which gives 
excellent soft tissue delineation with no radiation dose (Fig. 3). 
Figure 3. Side view MRI of the breast with contrast showing chest and blood vessels 
(MR Breast 2005). 
The use of MRI for breast imaging has been approved by the United States Food and 
Drug Administration (FDA) to help diagnose breast cancer since 1991 (MR Breast 2005). 
Breast MRI is most commonly used to investigate breast concerns detected with 
mammography, physical exam, or other imaging modalities. MRI breast exams are 
likewise extremely useful in examination of the augmented breast. This includes both the 
breast implant and the surrounding tissue of the breasts. MRI is valuable for staging 
breast cancer, helping to determine the most appropriate treatment, and for patient 
follow-up after breast cancer treatment. 
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Researchers are investigating whether breast MRI would be useful in screening 
younger women at higher risk of developing breast cancer. Women younger than 40 
years of age typically do not undergo mammography because of the high radiation 
exposure; monthly self breast examinations are considered sufficient. Some women, 
however, do suffer from a higher risk of breast cancer due to a strong family history or a 
mutated breast cancer gene, either BRCA 1 or BRCA 2. Women meeting these criteria 
should undergo some form of breast imaging before the age of 40. Since most young 
women have dense breast tissue, MRI may be a useful technology because of its 
effectiveness in distinguishing between dense tissue and tumors. However, currently the 
FDA has only approved mammography examinations to be used as a screening device for 
women with no symptoms of breast cancer. MRI is not approved by the FDA for 
younger women who may have an increased risk of breast cancer. 
One of mammography's shortcomings is that it loses sensitivity when screening 
younger women, specifically those with dense breast tissue (Mitka 2003). Screening 
mammography is less effective in identifying breast cancer in dense breast tissue because 
dense breast tissue turns up as a bright region, similar to the appearance of cancerous 
tumors. As women age, the breast tissue tends to become less dense, thus increasing the 
effectiveness of screening mammography. 
There has been recent debate about the amount of radiation dose a patient receives 
from routine screening mammography (Brenner et al. 2002). Glandular doses from 
screening mammography are typically low, usually less than 3 mGy of 26-30 kVp low-
energy x-rays. The dose varies depending on the size of the breast, with larger breasts 
receiving a slightly higher dose. 
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Because mammography consists of ionizing radiation, there is an increased risk of 
developing breast cancer associated with screening exams. This risk is due to the 
exposure the breast receives from low energy x-rays which result in a factor of two 
increase for developing breast cancer (Brenner et al. 2002). However, it is highly 
unlikely that the radiation risk alone is cause for major concern for mammography for 
those women greater than 50 years of age. 
While mammography uses low energy x-rays in imaging the breast, MRI uses 
powerful magnetic fields and radio waves to create images (MR Breast 2005). It is able 
to switch magnetic fields and radio waves to achieve views in any plane, yet 
mammography requires re-orientation of the breast and the mammography system for 
each view desired. Figure 4 depicts the normal breast imaging placement in MRI. The 
total MRI exam usually consists of a variety of Tl and T2 weighted sequences, which 
yields specific image orientations and specific types of contrast. 
* - " • • > 
K 
gps*"*-
'm m 
B. 
Figure 4. Image A shows a recent advancement in MRI breast imaging, the CP Breast 
Array Coil. This allows for bilateral breast imaging and improved differentiation 
between various breast tissues. With image B, the patient is placed directly on top of the 
table. The technologist has visual control of the breast position through a transparent 
window (MR Breast 2005). 
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Breast MRI has many benefits in helping to examine lesions and areas that may be 
missed by mammography, because MRI is highly sensitive to small abnormalities. A 
mammogram may reveal breast cancer in one area, but an MRI may show that the cancer 
is multi-focal, meaning small tumors are present in several areas of the breast. 
Determining the extent of breast cancer with MRI can help indicate the type of treatment 
the patient should undergo. Breast MRI is also useful in helping to determine how far the 
cancer has spread and to what areas, in addition to helping physicians determine cancer 
reoccurrences in women who have already been treated for breast cancer with 
lumpectomy. 
While MRI has significant promise as a supplemental tool to mammography in the 
diagnosis of breast cancer, it still has several hurdles to overcome in order to gain wider 
acceptance and use (Mitka 2003). Breast MRI is not always able to distinguish between 
cancerous and non-cancerous abnormalities, more commonly known as false-positives. 
This can lead to unnecessary breast biopsies. Also, a biopsy of an MRI detected 
abnormality can be difficult. Physicians will have to learn how to use MRI to guide them 
to the abnormality. Researchers and manufacturers are continuously trying to develop 
new MRI systems and tools to allow for better MRI guided breast biopsy because the 
abnormality found with MRI may or may not be visible with mammography. 
Breast MRI is unable to detect calcifications, while mammography can. 
Calcifications are tiny calcium deposits which can indicate the presence of breast cancer, 
typically associated with early stage breast cancers, such as ductal carcinoma in situ 
(DCIS). 
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Possibly the biggest drawback to using MRI, from a business perspective, is the cost. 
The average breast MRI costs approximately $1000. This is compared to approximately 
$100 per screening mammogram. Obviously to both the patient and insurance companies 
paying for the imaging procedure, a breast MRI needs to show significant benefits over 
mammography in order to justify the cost. Due to the current cost to benefit ratio, most 
community MRI centers do not perform breast MRI. However, new MRI systems 
designed specifically for the use of breast imaging are continuously being developed but 
are currently not widely available. 
Magnetic Resonance Spectroscopy 
MR Spectroscopy is the analysis of the shift, usually labeled as part per million 
(ppm), in resonance frequency of nuclei as a result of surrounding chemical bonds 
(Hendee and Ritenour 2002). Magnetic resonance spectroscopy (MRS) measures the 
differences in resonance frequencies among nuclei that occupy different positions in 
molecules. Each molecule resonates at a different frequency, due to their local magnetic 
fields. For example, on a 3.0 T spectrometer, N-acetyl aspartate (NAA) resonates at 2.0 
ppm, creatine resonates at 3.0 ppm, and choline resonates at 3.2 ppm (Brown and 
Semelka 2003). 
In spectroscopy, a broad range of radio frequencies is applied to the sample and a 
signal containing a range of frequencies is received (Hendee and Ritenour 2002). A 
Fourier transform is used on the return signal to determine what amplitude of each 
frequency is contained within the signal. All molecules and compounds are detected in 
the same magnetic field. 
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Proton MRS has started being used to help with breast cancer diagnosis. MRS 
provides the metabolic information about a visualized lesion in the breast (Lenkinski and 
Katz-Brull 2005). Thus, questionable lesions can be further examined without 
unnecessary biopsies. This not only helps the radiologist in their decision making, but 
also allows the patient to avoid the worry that is associated with questionable lesions. 
MRS coupled with MRI allows the radiologist to not only see the image of the lesion in 
the breast, but to also see the metabolic information of the lesion. A sample spectroscopy 
can be seen in Fig. 5. 
NAA 
Cho 
Cr 
— i 1 1 1 
4.0 3.0 2.0 1.0 
Chemical Shift (ppm) 
Figure 5. A proton spectra acquired on a 3.0 T system (Achieva 2007). 
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Magnetic Resonance Physics 
Every proton and neutron of a nucleus has a magnetic field because of their nuclear 
spin and charge distribution. When placed in an external magnetic field, the nucleus will 
resonate (Bushberg et. al 2002). This is because of the properties of the nuclei spin 
quantum number. Both protons and neutrons have a spin quantum number of V2 and thus, 
because hydrogen has one proton, it has two energy states (Brown and Semelka 2003). 
Those nuclei that have an odd number of nucleons have a magnetic moment, which is the 
magnitude and direction of the magnetic field with respect to the nucleus. 
A nuclear magnetic moment is generated from the nucleus of an atom since it is a 
spinning charged particle (Bushong 2003). Because the magnetic moment varies based 
on mass, charge of the particle and the rate at which it spins, each spin state has a 
different magnetic moment. Each spin state possesses the same energy until an external 
magnetic field is applied, at which point the spin states change energies. 
In the external magnetic field, the spin state is typically in the lowest energy state 
possible. This allows the spin states to be in equilibrium with the magnetic field. When 
an electromagnetic pulse is applied to the field that has the equal energy to that of the 
particles spin state energy gap, some of the particles in the lower energy state are excited 
to a higher energy state. As the pulse terminates, the spins in the higher energy field 
return to the lower energy state. This process of returning to the lower energy states is 
what produces the magnetic resonance signal. 
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Review of Related Literature 
There have been a few studies conducted that couple MRI with MRS to develop a 
more efficient way of detecting breast cancer. These studies have primarily been 
conducted on either 1.5 T or 4.0 T MR systems. The purpose of these studies was to 
improve the specificity of MR while maintaining the sensitivity. Sensitivity is how well 
an imaging system can detect subtle differences in anatomy, while specificity is the 
ability to precisely identify the reason for such differences (Bushong 2003). Magnetic 
resonance imaging of the breast is reported to have a sensitivity of 94-100% with variable 
specificity of 37-97% (Meisamy et al. 2005). Coupling MRI with MRS should increase 
the specificity. 
In these studies, patients underwent an imaging protocol that consisted of a Tl-
weighted, a T2-weighted scans, and a spectroscopy scan. The studies measured success 
in different ways. One method measured success by discovering if elevated levels of 
choline reflect an incidence of breast cancer (Bolan et al. 2003). Another method tried to 
discover if the elevated levels of choline could distinguish between benign and malignant 
breast lesions (Roebuck et al. 1998). Another method used known results of breast 
lesions and had radiologists determine the type of treatment that should be taken based on 
only looking at the MR images, and then looking at the MR spectroscopy with the MR 
image and determining if there should be a change in treatment (Meisamy et al. 2005). 
These previous studies have shown that there is a cutoff for tCho concentration of 1.03 
mmol kg" for distinguishing between benign and malignant lesions. A tCho 
concentration greater than 1.03 mmol kg"1 suggested malignancy and a concentration less 
than 1.03 mmol kg"1 suggested benignity. One other research method showed the 
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appearance of choline resonance peak based on the signal to noise ratio (SNR) of greater 
than two (Huang et al. 2004). An SNR equal to or greater than two was defined as a 
positive finding and a negative finding was defined as any SNR less than two. 
Choline is an amine which is found in the breast. The total choline containing 
compounds (tCho) consists of several different choline compounds: choline, 
phosphocholine, glycerophosphocholine, phosphatidylcholine, and sphingomyelin. Since 
elevated levels of tCho have also been found in a variety of human tumors, a measure of 
the tCho level can help radiologists determine if a lesion is cancerous (Roebuck et. al 
1998). The elevated levels of tCho vary, since different amounts of tCho are produced in 
the body depending on the individual. 
The goal of this research is to determine whether MRI coupled with MRS is an 
effective imaging protocol for the detection of breast cancer using a 3.0 T Philips 
spectrometer, the highest clinically approved magnetic field strength. Success of this 
study will be determined by accurately comparing mammography diagnosis with the 
diagnosis from MRI coupled with MRS. Further aim of this study is to show comparable 
results obtained from the 3.0 T system to a 4.0 T system. A favorable comparison 
between the two would show that MRI coupled with MRS for the detection of breast 
cancer is applicable today, instead of having to wait for the approval of a 4.0 T system for 
clinical use. 
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CHAPTER 2 
MATERIALS AND METHODS 
Patient Preparation 
Two groups of women between 18-80 years of age were imaged on a 3.0 T Philips 
Achieva MR spectrometer. The first group consisted of those women who were 
diagnosed cancer free, while the second were diagnosed with a form of breast cancer 
through conventional methods, i.e. mammography. Some women had a prior incidence 
of breast cancer and are currently in remission. These women were considered to be in 
the diagnosed cancer free group. 
A Philips Achieva 3.0 T clinical spectrometer located at the Nevada Imaging Center 
Spring Valley - Amigenics was used for imaging and spectroscopy scans on all subjects. 
MR imaging and MR spectroscopy measurements were made using a Philips bilateral 
breast coil. The coil is designed to have the patient lie in the prone position. 
The protocols used for each subject were a Tl-weighted, a T2 SPAIR SENSE scan 
which is a fat suppression scan, a spectroscopy scan, dynamic thrive scan, and a thrive 
post scan. The last two scans were conducted after contrast was injected into the patient. 
The contrast agent was gadolinium diethylenetriamine pentaacetic acid (GDPA). GDPA 
is the most commonly used contrast agent for MR Imaging. There are potential risks 
involved with it. Gadolinium based contrast agents can cause nephrogenic systemic 
fibrosis (NSF) which causes fibrosis in different tissues throughout the body. It most 
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commonly occurs in those individuals with acute or chronic severe renal insufficiency or 
dysfunction. However, the chance of developing an anaphylactoid reaction as the result 
of GDPA is 0.03-0.1%. While the risk is low, no patient was imaged who had any 
history of renal problems. All patients choosing to participate in the study were informed 
of the potential side effects by a physician before beginning the scans. The TR and TE 
used for each of the scans can be seen in Table 3. 
Table 3. MR scans parameters. 
Scan 
Tl-weighted 
T2 SPAIR 
Spectroscopy 
Dynamic Thrive 
Thrive Post 
TR (ms) 
425 
5874 
1500 
4.2 
1.8 
TE(m 
8.0 
120 
420 
2.1 
2.5 
The field of view varies with each patient. The total time for the MR imaging scans 
was approximately 20 minutes. Single voxel proton MR spectroscopy was performed 
using a slice of interest from the T2 SPAIR SENSE scan. The long echo time was used 
to help identify the choline peak, since this metabolite has a long T2 relaxation time. The 
long echo time also helps to eliminate the broad components of the water resonance. 
Water suppression was used to filter out the water resonance peak. With the water 
suppression, the total spectroscopy scan was approximately 10 minutes. The overall scan 
time varied for each patient depending on the size of the patient, the amount of tissue, the 
amount of fat, and the amount of water in the breast. 
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Radiologist Performance Study 
Two radiologists specializing in the area of breast cancer diagnosis participated in 
reading the MRI scans for this study. Both readers were blinded to any medical 
information about the participants. Current diagnosis from the last mammography scan 
was not known to the radiologists. Each patient's MR images were read by each 
participating radiologist. The radiologists made their recommended diagnosis without 
referring to one another, based on MR images. A recommended patient treatment follow-
up was also provided. These results were compared to the diagnosis made from the 
mammograms. The MR Spectroscopy scans recommendations were determined using 
the SNR from the choline peak on the graph. 
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CHAPTER 3 
RESULTS 
Patients 
Recruitment fliers were mailed out to patients of the Nevada Imaging Center Spring 
Valley - Amigenics, where the imaging scans took place. Six patients were chosen to 
participate in the study, one of which was not a patient of Nevada Imaging Center Spring 
Valley - Amigenics, but referred by a doctor employed with the imaging center and 
familiar with this study. The mean age of the patients was 53 years with an age range of 
43-69 years. All patients underwent a mammogram within the past year prior to their 
MR Imaging and Spectroscopy scans. All patients underwent an MRI scan on the Philips 
3.0 T Spectrometer except for the patient who was referred to us. The IRB protocol and 
their rights were explained to each patient. 
While a total of six patients were chosen to participate in this study, only four of the 
patients' results were included in the final analysis. This is due to a variety of reasons. 
The fifth patient who participated in this study was not included due to issues with 
digitizing her mammograms. The patients provided their most recent mammography 
scans, which were scanned into the computer database system at the Nevada Imaging 
Center Spring Valley - Amigenics. During the time period when the radiologists were 
preparing to read the scans, and before the scans were transferred to each of the 
radiologist's computer system, the computer containing all of the patients' MRI, MRS, 
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and mammography scans became inoperable. All of the scans for each patient were lost 
at this time. Eventually, after rebuilding the system, the information was recovered. 
However, the information for patient five was corrupt and incomplete. Much time was 
spent trying to recover and restore the original scans for this patient, but some of the data 
was permanently lost. The rest of the data that wasn't corrupt contained not enough 
information to be able to send to the radiologists for their readings. Since further 
inconveniencing the patient was not an option this patient was removed from the study. 
Patient six was excluded from this study due to major difficulties handling outside 
MRI and mammography image data sets. While it was possible to examine the 
mammography and MRI scans and load them into the computer system at the imaging 
center, it was not possible to anonymize the scans. Since anonymizing the patient's scans 
was part of the protocol to both maintain patient privacy and abide by the Health 
Insurance Portability and Accountability Act (HIPAA), it was not possible to have this 
patients MRI and mammography results analyzed by the radiologists. Therefore, patient 
six was not included in the final results for this study. 
There were also minor complications with the remaining four patients; however these 
complications did not prevent them from participating in this study. Out of the remaining 
four patients, only two of them, patient two and four, completed all of the scans. That is, 
they had a mammography completed within the year prior to undergoing the MRI and 
MRS and were able to deliver the films and radiologist's report from the mammography 
scan. They also both had MRI and MRS scans that were completed with the MRI results 
being read by two radiologists. 
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To determine which imaging protocols were ideal for breast MR Imaging coupled 
with MR Spectroscopy, different scans were investigated. Patient two completed all 
aspects of the study, but an additional T2-weighted scan was also performed. This 
patient was imaged early in the study while the imaging protocols were still being 
developed. At that time, it was thought the T2-weighted scan would help in identifying a 
suspicious lesion for a spectroscopy scan on because water and other fluid containing 
tissues are bright on this scan. The T2 SPAIR SENSE is a fat suppression scan which 
also made these tissues bright. After seeing the results of the T2-weighted scan and 
comparing it to the T2 SPAIR SENSE scan, it was decided to delete the T2-weighted 
scan, as it offered no benefit for either the MR technician performing the scan or for the 
radiologists reading the scan. It was decided to proceed with the patients from that point 
forward without the T2-weighted scan. The MR technician who conducted the imaging 
scans did not perform spectroscopy during the development of the protocol, and therefore 
one patient did not receive it. Once a final protocol was established with the MR 
Imaging and MR Spectroscopy scans, no additional scans were conducted and all of the 
scans in the protocol were performed. 
The second patient who also completed all aspects of the study was patient four. This 
patient was imaged during the later stages of the study. For both patient two and patient 
four, the spectroscopy scan was conducted before the contrast injection so there would be 
no chemical interference with the selected voxel. A physician discussed the benefits and 
potential drawbacks of the contrast with each patient. A licensed technician performed 
the contrast injections and a physician was present during and after the entire scan time, 
in case the patient had a late reaction to the contrast agent. The mammography and MR 
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Imaging with and without contrast scans were all read by two radiologists. The MR 
Spectroscopy scan was analyzed by using previous literature, specifically the study 
conducted by Huang et al. 2004. 
The other two patients whose results were chosen to be read by the radiologists had 
incomplete scans. Patient one was the first patient who was scanned as part of this study. 
The patient had a mammography scan within the year prior to having the MRJ scan, but a 
copy of the films was never received from the patient and repeated attempts to obtain 
them were unsuccessful. It was decided to continue with the MRI scan with the hope of 
receiving the mammography films at a later date, but the films were still never received 
from the patient. Also during the scan, the MR technician did not perform the 
spectroscopy scan. The results from the MR Imaging scan were analyzed by both 
radiologists, but obviously no comparison can be made to the missing mammography 
scans. The lack of spectroscopy prevented the verification of the BI-RADS (Breast 
Imaging Reporting and Database System) diagnosis with the MRI scans. 
The other patient who had incomplete results was patient three. The patient had 
incomplete results for different reasons than the first patient. This patient did deliver the 
mammography films to be scanned into the computer system at the imaging center. The 
patient then had both the MR imaging and spectroscopy scans completed with contrast. 
All scans were confirmed to be present. However, there was a problem with the data 
when the computer system crashed. While the mammography films that had been 
scanned in and the MR Imaging scans with the contrast agent were able to be recovered, 
the spectroscopy scan was lost. Again, a great deal of time was spent trying to discover 
why the MR Imaging scans were able to be recovered while the spectroscopy was not. It 
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was decided to proceed with only the mammography and MR Imaging scans. While 
there were two patients who had complete results that were going to be analyzed by the 
radiologists, both of those patients were thought to have either benign tumors, cysts, or 
no findings, patient three was known to have a BI-RADS diagnosis of 5 with malignant 
tumors present from the mammography scan. Having this patient's spectroscopy scan 
would have helped to confirm the malignant tumors seen in the mammography scan by 
analyzing the choline level as well as helping to measure the effectiveness of MR 
imaging coupled with spectroscopy. Table 4 lists the different BI-RADS categories and 
the respective diagnosis and criteria for each one. 
Table 4. BI-RADS Scores (American College of Radiology 2003). 
Category Diagnosis Criteria 
Not enough information to 
make a diagnosis 0 Incomplete 
1 Negative Nothing to comment on 
2 Benign Definite benign finding 
3 Probably benign Finding has high probability 
of being benign 
Reasonable probability of 4 Suspicious abnormality 
being malignant 
TT. , . . . ~ ,. High probability of being 
5 Highly suspicious of malignancy ~! r 
6 Known biopsy proven malignancy Known to be malignant 
In regards to patient three it should be noted that mammography did not miss the 
malignant tumors. Upon talking to the patient about their medical history, it was 
discovered the patient had not undergone a mammography scan in over five years. 
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MR Imaging and Spectroscopy Results 
Table 5 shows the results of each patient scanned. As can be seen in the table, only 
two of the four patients completed all aspects of the study. The mammography BI-RADS 
reading, two MRI BI-RADS reads by radiologists, and the spectroscopy level are all 
included. The spectroscopy level is determined using the SNR. An SNR of greater than 
or equal to 2.0 indicates a positive finding and an SNR of less than 2.0 indicates a 
negative finding. Any of the exams where patients' results were unavailable or not 
completed are marked with an X. 
Table 5. Mammography and MRI findings using BI-RADS score. MRS 
findings used SNR score. MR Imaging scans were read by two radiologists. 
Patient 
Patient 1 
Patient 2 
Patient 3 
Patient 4 
Mammogi 
X 
2 
5 
1 
raphy MR Imaging 
3 
2 
5 
1 
1 MR Imaging 
3 
2 
5 
1 
2 MR Spectroscopy 
X 
1.3 
X 
0.1 
An X signifies exam either not completed or unavailable 
Patient 1 received a BI-RADS score of 3 from each radiologist reading the MRI 
scans. Mammography and spectroscopy were unavailable for this patient. The BI-RADS 
score of 3 indicates that lesions are present in the breast and have a high probability of 
being benign. Figure 6 shows selected slices from each of the scans the patient 
underwent. The bright spots in the images indicate the lesions in the breast and help the 
radiologist diagnosis. Since the tumors are probably benign, a six month follow-up is 
recommended. 
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Figure 6. Patient 1 images from each scan performed. A) is slice 34 from the Tl-
weighted scan. B) is slice 34 from the T2 SPA1R scan. C) is slice 317 from the Dynamic 
Thrive scan. D) is slice 116 from the Thrive Post scan. 
Patient 2 received a BI-RADS score of 2 from the radiologist reading the 
mammography scan and a BI-RADS score of 2 from each of the radiologists reading the 
MRI scans. The BI-RADS score of 2 indicates lesions or calcifications are present in the 
breast but are definitely benign. Figure 7 shows selected slices from each of the MR 
scans the patient underwent. The bright spots in the images indicate the presence of the 
benign lesions in the breast. Because the tumors are known to be benign, annual routine 
screening is recommended, corresponding to the SNR of 1.3 for the spectroscopy scan. 
Spectroscopy results were only available for two of the four patients. The patients 
whose results were available were patient 2 and 4 as listed in Table 5. The results from 
the MR image for patient 2 show the possibility of tiny cysts within the selected voxel. 
The spectroscopy conducted on this patient shows a SNR of 1.3, indicating a negative 
finding. Based on the mammography scan, both radiologists' reads of the MR imaging 
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scans, and the low SNR level, a recommendation of continued annual screening 
mammography was recommended. Figure 8 shows the MR image of patient 2 as well as 
its corresponding MR Spectroscopy scan. 
Figure 7. Patient 2 images from each scan performed. A) is slice 34 from the Tl-
weighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 405 from the Dynamic 
Thrive scan. D) is slice 95 from the Thrive Post scan. 
Figure 8. The MR image and spectroscopy results for patient 2 are shown in A) and B). 
The MR image in A) shows the voxel that was chosen outlined in the box on the left 
breast. In B), the choline peak is highlighted in the spectroscopy graph at 3.2 ppm, the 
position of tCho in a 3.0 T spectrometer. The SNR of 1.3 indicates a negative finding. 
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Patient 3 received a BI-RADS score of 5 from the radiologist reading the 
mammography scan and a BI-RADS score of 5 from each of the radiologists reading the 
MRI scans. The BI-RADS score of 5 indicates lesions are present in the breast and have 
a high probability of being malignant. MR images can be seen in Figure 9. A fairly large 
tumor can be seen in the left breast in the T2 SPAIR scan. The same tumor is seen even 
more clearly in the two contrast scans along with several other small lesions. For this 
diagnosis, appropriate action should be taken, whether it includes immediate surgery 
without biopsy, oncology treatment, or a different treatment method. Ultimately, the 
treatment method will be different for each patient. Spectroscopy was unavailable for 
this patient. Figure 9 shows selected slices from each of the scans the patient underwent. 
Figure 9. Patient 3 images from each scan performed. A) is slice 34 from the Tl-
weighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 317 from the Dynamic 
Thrive scan. D) is slice 77 from the Thrive Post scan. 
Patient 4 received a BI-RADS score of 1 from the radiologist reading the 
mammography scan and a BI-RADS score of 1 from each of the radiologists reading the 
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MRI scans. The BI-RADS score of 1 indicates there are no lesions or suspicious 
calcifications present in the breast and therefore nothing to comment on. Since no 
masses are seen, annual routine screening is recommended, corresponding to the SNR of 
0.1 for the spectroscopy scan. Figure 10 shows selected slices from each of the scans the 
patient underwent. 
Figure 10. Patient 4 images from each scan performed. A) is slice 34 from the Tl-
weighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 317 from the Dynamic 
Thrive scan. D) is slice 77 from the Thrive Post scan. 
The results from the MR image for patient 4 identified no tumors or cysts. 
Spectroscopy was performed on the patient and an SNR of 0.1 was found, indicating a 
negative finding. Based on the mammography scan and both radiologists' reads of the 
MR imaging scans, and the low SNR level, a recommendation of continued annual 
screening mammography is still recommended. Figure 11 shows the MR image of 
patient 4 as well as its corresponding MR Spectroscopy scan. 
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Figure 11. The MR image and spectroscopy results for patient 4 are shown in A) and B). 
The MR image in A) shows the voxel that was chosen outlined in the box on the left 
breast. In B), the choline peak is highlighted in the spectroscopy graph at 3.2 ppm, the 
position of tCho in a 3.0 T spectrometer. The SNR of 0.1 indicates a negative finding. 
It is also possible to have a false positive with MR Spectroscopy. An SNR of greater 
than 2 can still be a negative finding, but it would be unknown whether it was a negative 
finding until after a biopsy was performed. A high SNR indicating the presence of a 
tumor could be due to several reasons, such as interference from other breast tissue in the 
voxel or the voxel not being an appropriate size for the suspected lesion. 
Protocols 
The breast MRI and MRS protocol took some time to develop because the Nevada 
Imaging Center Spring Valley - Amigenics does not offer breast MRI or MRS. A 
mixture of scans were initially used, but eventually discarded because they either 
revealed no beneficial information or had similar parameters to other scans and were 
therefore unnecessary. After several different scans were added or subtracted from the 
protocol, the researcher for this study decided on the final protocol that consisted of a Tl-
weighted, T2 SPAIR, Spectroscopy, Dynamic Thrive, and a Thrive Post scan. All four 
patients underwent each of the scans with the exception of patient 1 who did not have 
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spectroscopy conducted. Patient 3 completed all of the scans but the spectroscopy was 
lost when the computer system was inoperable. 
Figures 6, 7, 9, and 10 show selected slices from each of the patients. The slices 
represented for each patient were chosen based on the image from each scan showing the 
most detail. Image A) in each of the figures is the Tl-weighted scan. Each of the Tl-
weighted images appears bright, emphasizing the fat in the breast. The fat is easily seen 
in each patient, enabling the radiologist when looking at other scans to easily see if a 
potential lesion is actually fat by referring to the Tl-weighted scan. Water and other 
fluids in the breast appear as dark intensity in each of the figures. 
Image B) in each of the figures is the T2 SPAIR scan. Fat appears as a dark intensity 
and water and other fluids appear as bright intensities. The T2 SPAIR is a fat 
suppression scan which helps to emphasize the water in the breast as well as enhance any 
lesions that might be present. Since fat and water have different resonances, the fat is 
suppressed by introducing a prepulse to eliminate the quadrupole effects on fat 
suppression. The fat suppression adds to the overall scan time, but is vital in order to 
achieve the image quality seen in the images. With the fat suppressed, lesions appear 
bright and are easier to differentiate from water and other fluids that are present. 
Image C) in each of the figures is the Dynamic Thrive scan. This is a Tl scan that 
has had gadolinium added as a contrast agent. The dynamic thrive scan is a quick scan 
showing the uptake of the agent in the breast almost immediately after it has been 
administered. Since the contrast agent is typically seen in the malignant and benign 
lesions in the breast before any other areas, a quick scan can help the radiologist easily 
differentiate the lesions from other areas in the breast. 
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Image D) in each of the figures is the Thrive Post scan. It is also a Tl scan aided with 
the use of a gadolinium contrast agent. This scan is an appropriate follow-up scan to the 
Dynamic Thrive scan because it still has the benefits of the contrast agent uptake in the 
lesions, but also the contrast has been absorbed by the rest of the breast by this point in 
the scanning protocol. It offers more detail to the overall breast while still showing the 
lesions as bright spots. 
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CHAPTER 4 
CONCLUSIONS 
MR imaging for the detection of breast cancer has shown promise but there are issues 
still associated with it, such as time of exam, cost, and false positives, that overall make it 
an imaging modality that does not currently offer the screening benefits of 
mammography. The use of MR spectroscopy for the detection of breast cancer is still a 
fairly new concept and is not widely utilized. However, MR imaging coupled with MR 
spectroscopy is showing promise. 
While there were only a small number of patients scanned for this study, there are 
positives voiced by the patients. All of the patients liked the fact that the MRI offered an 
alternative to the breast compression associated with mammography scans in order to 
produce the best possible image. The ease of the entire exam was also cited as a positive 
by all patients. The patients also expressed enthusiasm with regards to the fact that there 
is no radiation dose from the MR imaging or spectroscopy exams as is the case with 
mammography. 
There were also some negatives about the exam that some of the patients noted. The 
primary concern about the exam was the length of time. While a mammography scan can 
take as little as 10 or 15 minutes, the MRI and MRS exams take approximately 30-40 
minutes. The patients that received a contrast injection also cited this part of the exam as 
a negative. Specifically, the patients didn't like the fact that the needle was placed into 
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their hand during the prep before the scan took place, and then they had to wait until the 
part of the scanning protocol to receive the injection before the needle was removed. The 
MRI bore can also get extremely loud during some of the exams and this was noted as 
more of an annoyance as opposed to a negative. 
One major complication with regards to this study was the lack of patients. This was 
due to several reasons. The most common complaint from potential patients was the time 
the imaging and spectroscopy scans would take place. Most of the exams had to be 
conducted at night. This was because the Philips 3.0 T spectrometer is in high demand 
due to the rarity of the magnetic strength in the Las Vegas valley and the quality of 
images that can be seen from it. The MRI is in use seven days a week for approximately 
16 hours a day, leaving only a small window at night when it was available to be used for 
research purposes. Many potential patients said the only time available for them to 
volunteer for the study was during normal day time hours. Therefore the time of the 
exams was a turnoff for many potential patients. Several potential patients were unable 
to be imaged due to metal objects being located inside their bodies and the concern the 
magnets could potentially cause physical harm. 
Because of the small number of patients and the incomplete scans for a couple of 
them, it is hard to measure the diagnostic performance of MR spectroscopy. The two 
patients who completed all the scans, mammography, MR imaging, and MR 
spectroscopy, show MR imaging and spectroscopy to be effective methods. Both patients 
MR images read by the radiologists confirmed the recommendations of the radiologist 
who read the mammography scans. The results from the spectroscopy graphs also 
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confirmed these results, indicating that MR imaging coupled with spectroscopy is an 
effective imaging modality for diagnosing breast cancer. 
MR Spectroscopy helps to determine the diagnosis and recommended follow-up for 
the patient, but does have a drawback seen in this study. Patient four had been diagnosed 
as a BI-RADS 1 from the mammography scan, indicating a negative finding. Since a 
negative finding means there is nothing to report, it is difficult to run spectroscopy if 
there are no lesions present. The use of MRI does help to see lesions that may go 
undetected with mammography, but could also produce the same result. In these cases 
where the patient clearly has no lesions present and is a negative finding, it is probably 
not worth the either the MR technologist or the patients' time to undergo this scan. More 
research is needed to determine if this is valid conclusion or just a rare case that appeared 
in this study. 
Though the number of patients was low, some findings can be noted. Both of the 
radiologists were in agreement with each other as to the BI-RADS diagnosis. While MRI 
for the detection of breast cancer is not widely used, radiologists coming to the same 
conclusion while not previously seeing a large number of MRI breast scans shows 
promise that these image sets are not too complicated to analyze for the inexperienced. 
This is especially a good sign since the four patients each had a different diagnosis, yet 
the radiologists still came to the same conclusions. 
The use of the gadolinium contrast agent is a definite must for any breast MRI 
protocol. The contrast agent uptake in the breast by the lesions clearly helps the 
radiologist identify not only obvious larger lesions seen in the Tl-weighted and T2 
SPAIR scans, but also smaller lesions that may have gone unnoticed. The Tl-weighted 
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and T2 SPAIR scans should also be included in the protocol due to the benefits of 
differentiating the tissue relaxation times in the breast. The fat tissue appearing as a 
bright intensity in the Tl-weighted scan and water and other fluids appearing as bright 
intensity in the T2 SPAIR again help to differentiate the different tissues and fluids that 
make up the breast and aid the radiologist in making a better diagnosis and recommended 
follow-up. 
Previous studies of MR imaging coupled with spectroscopy for the detection of breast 
cancer have been primarily conducted on 1.5 T spectrometers, with a few studies 
conducted on a research based 4.0 T spectrometer. Obviously the number of patients 
used in the study is not ideal, and a larger volume would produce more complete results, 
the few patients that imaged show positive results and incentive to continue the research 
on a broader scale. The MR image exams were consistent with the mammography BI-
RADS results. The spectroscopy results both confirmed that any suspected lesions 
discovered and analyzed within the voxel area were negative findings. 
There needs to be continued research conducted with MR Imaging coupled with MR 
Spectroscopy, but the use of a contrast agent is essential for helping to emphasize 
potential lesions in the breast. Continued research on a 3.0 T spectrometer will help to 
conclude whether MR Imaging coupled with Spectroscopy is an effective imaging 
modality for the detection of breast cancer. 
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OF BB8&WCH SUBJECTS 
TITLE OF STUDY: Investigation of Magnetic Resonance Imaging and Spectroscopy for the 
Detection of Breast Cancer 
INVESTIGATOR(S): Robert Etnire. Phillip Fatten 
CONTACT PHONE NUMBER: 702-895-3555 (Phillip Patton), 702-869-S889 (Rob Etnirc) 
Purpose of the Study 
You are invited to participate in a research study. The purpose of this study is to investigate Magnetic 
Resonance Imaging (MRJ) as a new methodology for identifying breast cancer using various imaging 
procedures. 
Participants 
You are being asked to participate in the study because your mammography scans have indicated the 
possibility of breast cancer, or you are healthy and have not been previously diagnosed with breast 
cancer and are between the ages of 18 and 80 with no known medical conditions such as pregnancy, 
metal implants, claustrophobia, etc., that would prevent you from being imaged by MRI. 
Procedures 
If you volunteer to participate in this study and are selected, you will be asked to do the following: lie 
on your stomach for approximately 45-60 minutes while the imaging procedure is occurring and 
complete a questionnaire about your medical history and a questionnaire about the procedure. 
Benefits of Participation 
There may not be direct benefits to you as a participant in this study. However, we hope to leant that 
Magnetic Resonance Imaging coupled with Magnetic Resonance Spectroscopy is effective for the 
diagnosis of breast cancer, thus reducing the radiation exposure women receive from their annual 
mammograms. 
Risks of Participation 
There are risks involved in all research studies. This study may include minimal risks. It is possible 
that some participants may experience claustrophobia during the procedure. Additionally, participants 
may fall while getting on or off the imaging table. Subjects may feel uneasy about the medical history 
questionnaire as well. 
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Department of Health Physics 
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1111 # 
TITLE OF STUDY: investigation of Magnetic Resonance Imagine and Spectroscopy for the 
Detection of Breast Cancer 
INVESTIGATORS): Robert Etnire, Phillip Patton 
CONTACT PHONE NUMBER: 702-895-3555 (Phillip Patton), 702-869-588') (Rob Etnire) 
Cost •/Compensation 
There will not be a financial cost to you to participate in this study other than time and money needed 
to travel to and from she imaging center. The study will take approximately 45 - 60 minutes of your 
time. You will not be compensated for your time. The University of Nevada, Las Vegas may not 
provide compensation or free medical care for an unanticipated injury sustained ax a result of 
participating in this research study. 
Contact Information 
If you have any questions or concerns about the study, you may contact Robert Etnire at 702-869-
5889 or Phillip Patton, PhD at 702-895-3555. For questions regarding the rights of research subjects, 
any complaints or comments regarding the manner in which the study is being conducted, you may 
contact the UNLV Office for the Protection of Research Subjects at 702-895-2794. 
Voluntary Participation 
Your participation in this study is voluntary. You may refuse to participate in this study or in any pan 
of this study. You may stop participating in this study at any time for any reason without prejudice to 
your relations with the university. You are encouraged to ask questions about this study at the 
beginning or any time during the research study. 
Confidentiality 
All information gathered in this study will be kept completely confidential. No reference will be made 
in written or oral materials that could link you to this study. All records will be stored in a locked 
facility at UNLV for at least 3 years after completion of the study. After the storage time the 
information gathered will be shredded. 
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Participant Consent: 
I have read the above information and agree to participate in this study. I am at least \V> years of age 
with no medical conditions (pregnant, metal implants, claustrophobia, etc.) that prevent me from being 
imaged using a magnetic resonance imaging spectrometer. A copy of this form has been given to me. 
Signature of Participant Date 
Participant Name (Please Print) 
Participant Note: Please do not sign this document if the Approval Stump is missing or is expired. 
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Imaging and Spectroscopy Scans 
1. Select 'Patient' on the menu bar. 
2. Select'New Exam.' 
3. Enter the following information: 
a. Patient's coded name. 
b. Registration number. 
c. Patient's date of birth (MM/DD/YYYY). 
d. Patient gender as female. 
e. Patient's weight (in kg). 
f. Any additional comments. 
g. The other fields can be left blank. 
4. Clink'Enter.' 
5. Click 'Proceed.' The system will not automatically switch to scan mode. 
6. Select the 'Hospital' folder in the Exam Cards. 
7. Select the folder 'User Defined 3.' 
8. Scroll down and select the 'Breast' folder. 
9. Select the first scan list 'Breast.' 
10. Copy the scans and paste them in the Exam Cards. 
11. Delete all scans except the Survey, RefSBrst, sTlW_TSE_Tra, sT2W_TSE_Tra, 
DYNTHRIVE SENSE, THRIVEHR POST SENSE. These are the only 
imaging scans that are needed. 
12. Next, add the spectroscopy scan. 
13. Select the 'Hospital' folder in the Exam Cards 
14. Select the 'Thorax' folder. 
15. Copy and paste the 'Breast Spectroscopy' scan into the Exam Cards, placing it 
after the sT2W_TSE_Tra scan and before the DYNTHRIVE SENSE scan. The 
scan is named SV_PRESS_270. 
16. In the Exam Cards, click on 'Status' for the Survey scan to open up the scan. 
Click 'Proceed' to start the Survey scan. The Survey scan will now begin. 
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17. When the Survey has finished, click on 'Status' in the Exam Cards for the 
RefSBrst to open up the scan. Click 'Proceed' to start the Ref_SBrst scan. The 
RefSBrst scan will now begin. 
18. When the RefSBrst has finished, click on 'Status' in the Exam Cards for the 
sTIWTSETra to open up the scan. Select the 'Parameter Editor' on the Exam 
Cards Toolbar. Under the 'Initial' tab, use the Survey scan as a guide and adjust 
the field of view (FOV) to the size of the breast. Under the 'Geometry' tab, turn 
SENSE off and change the Matrix scan to 256. Click 'Proceed' to start the 
sTIWTSETra scan. The sTlW_TSE_Tra scan will now begin. 
19. Repeat the steps used for the sTIWTSETra for the T2 SPAIR SENSE, 
DYNTHRIVE SENSE, and THRIVEHR POST SENSE. The previous scans 
do not need to be finished to edit the following scans, with the exception of the 
SVPRESS270 scan. If the previous scan has not finished and the edit has been 
completed for the following scan, click 'Proceed' for this scan. It will start 
automatically once the previous scan has finished. 
20. Once the T2 SPAIR SENSE has been completed, click on 'Status' in the Exam 
Cards for the SVPRESS270 to open up the scan. Select a slice from the T2 
SPAIR SENSE that shows the suspicious area where the spectroscopy will be 
performed. A red box will appear in about 10-20 slices. This is the voxel box 
where the spectroscopy will be performed. Try to conform the voxel box to the 
exact size of the suspected area. Click 'Proceed' to start the SVPRESS270 
scan. The SV_PRESS_270 scan will now begin. 
21. The software will automatically adjust for the water suppression. 
22. Following the water suppression, the scan will now begin. 
23. When the SVPRESS270 scan has been completed, the contrast should be 
administered. Once the injection is complete, start the DYNTHRIVE SENSE 
scan. The scan preparation should have already been completed as stated in step 
19. 
24. Once the DYNTHRIVE SENSE scan has been completed, the THRIVEHR 
POST SENSE will begin. This is the last scan in the protocol. 
25. Once the protocol is completed, click on the 'Advance Processing Button' next to 
the patient name. 
26. Double click on the figure of the peaks. This will load the spectroscopy curve 
into the main window. 
27. Click 'Run Script.' This will load the graph for the voxel. 
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The protocol being used consists of the following scans 
Survey 
RefSBrst 
Reference scan for bilateral SENSE Breast coil 
-The sensitivity information obtained in this scan is used for all 
CLEAR reconstructions during the entire exam. 
Tip: 
If large patient movement has occurred, the reference scan should 
be repeated. 
Tra 
weighted turbo spin echo (TSE) sequence of the breast 
- The V stands for single shot 
- Due to CLEAR, the axillae can also be clearly visualized 
- Randomized shots are used to minimize motion artifacts 
T2 SPAIR SENSE 
A T2 fat suppression scan 
SVPRESS270 
MR spectroscopy scan 
DYNTHRIVE SENSE 
Tl weighted scan with contrast 
THRIVE HR POST SENSE 
T1 weighted scan with contrast 
Patient Positioning 
1. Place the couch in the parking position by using the Out/Down tumble switch on 
the control panel. If imaging a heavy patient, do not place the couch in the 
parking position. Instead, place a couch about 15 cm from its lowest point. 
2. Place the breast coil on the couch. Do not plug the coil into the scanner at this 
time. For comfort, place a few pillows at the head of the couch for the patient to 
rest their head on and place the coil directly behind these pillows. Place the breast 
mattress directly behind the coil. Add any other mattress as needed for patient 
comfort. Be sure the patient is as comfortable as possible to minimize motion 
artifacts. Blankets or sheets may be used as the room may become cool during 
the procedure. 
sTlW_TSE_ 
ATI 
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3. Have the patient remove any metal items they are wearing. Give the patient a 
gown to wear with the opening in the front. The patient must not wear a shirt or 
bra during the procedure. Give the patient earplugs for their protection. The 
acoustic noise levels may cause some discomfort for patients without earplugs. 
4. Have the patient lie down in the prone position on the couch. The breasts should 
be placed in holes in the coil and hang freely. The gown can hang on the sides of 
the coil, but cannot be in the coil holes. 
5. Press the 'light visor' button on the control panel. This will activate the laser 
beams. Raise the couch using the Up/In tumble switch. Using the laser beams, 
place the patient so the breasts lie in the middle of the illuminated cross. Press 
'Travel-to-scanplane' button on the control panel. The laser beams will turn off 
automatically. Use the Up/In tumble switch to place the patient into the tube. 
The couch will stop moving once the isocenter has been reached. The coil may 
now be plugged into the scanner. 
6. Once all the scans have finished, remove the patient from the tube. Use the 
Out/Down tumble switch on the control panel until the couch is in the parking 
position. If imaging a heavier patient, stop the couch at about 15 cm above the 
lowest level. 
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APPENDIX III 
MRI DEFINITION OF TERMS 
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CLEAR 
• Stands for Constant LEvel AppeaRance 
• Provides a superb uniformity correction 
• It is automatically implemented in all SENSE protocols 
• Requires that a reference scan be performed. The reference scan provides a 
sensitivity map of the coil enabling the system to calculate the exact signal 
contribution to each pixel of the image. 
SENSE 
• Stands for SENSitivity Encoding 
• Potential benefits include: 
• Shorter scan times 
• Higher temporal resolution 
• Improved spatial resolution 
• Less motion and susceptibility artifacts 
SPAIR 
• Stands for SPectral Attenuated Inversion Recovery 
• Fat suppression technique 
SNR 
• Stands for Signal to Noise ratio 
• Measure of image quality 
THRIVE 
• Stands for Tl High Resolution Isotropic Volume Excitation 
• Used with contrast for dynamic studies 
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APPENDIX IV 
COPYRIGHT PERMISSION LETTERS 
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National Cancer Institute 
Original Message 
From: NCI Cancer.gov Staff <cancer.gov_staff@mail.nih.gov> 
To: rel82@aim.com; Rel82@aol.com 
Sent: Fri, 9 Mar 2007 11:28 am 
Subject: RE: Cancer.gov Inquiry - Copyright Information 
This follow-up message is in response to the e-mail you recently sent 
to the 
National Cancer Institute's (NCI) Web site, http://www.cancer.gov, 
regarding 
acknowledgement requirements for the use of content on our site. We 
apologize 
for the delayed response. Both of the illustrations you mentioned 
(http://www.cancer.gov/cancertopics/wyntk/breast/page2 and 
http://training.seer.cancer.gov/ss moduleOl breast/unit02 secOl anatomy 
_Jrtrnl) 
are in the public domain and may be used freely. Acknowledgement of 
the sources 
is appreciated, but not required. 
We prefer the following format when referencing content in the "What 
You Need To 
Know About(tm) Cancer" publications: 
National Cancer Institute. What You Need To Know About(TM) Breast 
Cancer 
(http://www.cancer.gov/cancertopics/wyntk/breast). Posted 07/30/2005. 
Source acknowledgement for information from the SEER Training Web site 
may be 
stated as follows: 
From http://www.training.seer.cancer.gov; funded by the U.S. National 
Cancer 
Institute's Surveillance, Epidemiology, and End Results (SEER) Program, 
via 
contract number N01-CN-67006, with Emory University, Atlanta SEER 
Cancer 
Registry, Atlanta, Georgia, U.S.A. 
We hope this information is helpful. 
National Cancer Institute Staff 
NOTE: You may get an error message when clicking on the URL link(s) in 
this 
e-mail. If you copy and paste the full URL into your browser window, 
you should 
not have a problem opening the link. 
From: re!S2@aim.com [mailto:rel82@aim.com] 
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Sent: Monday, March 05, 2007 7:31 PM 
To: NCI Cancer.gov Staff 
Subject: Re: Cancer.gov Inquiry - Copyright Information 
Thank you for your help. I look forward to your reponse. 
Robert Etnire 
Original Message 
From: cancer.gov staff@rnail.nih.gov 
To: RelW@aol.com 
Sent: Mon, 5 Mar 2007 1:06 PM 
Subject: RE: Cancer.gov Inquiry - Copyright Information 
This message is in response to the e-mail you recently sent to the 
National Cancer Institute's (NCI) Web site, http://www.cancer.gov, 
regarding the use of content posted on our site. 
We are trying to find out if the two illustrations you mentioned are in 
the public domain. If they are in the public domain, no copyright 
forms 
will need to be completed. If the illustrations are not in the public 
domain, we will try to provide contact information for the owner of the 
illustrations. 
We apologize for the delay and will send a response as soon as 
possible. 
Thank you for your patience. 
National Cancer Institute Staff 
NOTE: You may get an error message when clicking on the URL link(s) in 
this e-mail. If you copy and paste the full URL into your browser 
window, you should not have a problem opening the link. 
Original Message 
From: Rel82@aol.com [mailto:Rel82@aol•com] 
Sent: Wednesday, February 28, 2007 11:34 AM 
To: NCI Cancer.gov Staff 
Subject: Cancer.gov Inquiry - Copyright Information 
Message: To whom it may concern: 
I am a graduate student at UNLV. I am currently working on my thesis 
and I would like to include two images from your website in my research 
paper. In order to do so, I would need permission from you to use the 
image. The images I would like to use can be found at these websites: 
http://www.cancer.gov/cancertopics/wyntk/breast/page2 and 
http://trainirig.seer.cancer.gov/ss moduleOl breast/unit02 secOl anatomy 
html. I can send the copyright page that would need to be filled out, 
signed, and mailed to me as an attachment in an email. The copyright 
page will be included in my thesis granting me permission. If 
possible, 
can you please send a reply to my email address letting me know about 
your decision. Also, if you do grant me permission, the sooner I 
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receive the filled out copyright form, the better. Thank you in 
advance 
for your help. 
Robert Etnire 
7937 Terrace Rock Way #101 
Las Vegas, NV 89128 
re!82@aol.com 
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American Cancer Society 
March 12, 2007 
American Cancer Society 
Attention: Reprints 
To whom it may concern, 
My name is Robert Etnire and I am a graduate student at the University of Nevada, Las 
Vegas. I am currently working on my thesis and will like to include some information from 
your website in it. I am researching the use of MRI coupled with MRS on a 3.0 T 
spectrometer for the detection of breast cancer. The research is in support of my thesis to 
earn my Master of Science degree in Health Physics. 
I am requesting to use a table from the pdf file titled "Breast Cancer Facts and Figures 2005-
2006." Specifically, I am requesting the use of Table 2. Estimated New Breast Cancer Cases 
and Deaths in Women by Age, US, 2005. The document is located at the web address: 
http://\\n\^v.cancer.ofg/downloads/STT/CAFF2005BrFacspdf"2005.pdf and a copy of the 
table is on page 3 of this document. Page 3 from this document has been included as part 
of the fax. 
The table will be included in its entirety in my thesis as background information detailing the 
number of people by age stricken with breast cancer, as well as the number of deaths from 
it. The table will be cited both in the text and in a references page at the end of the thesis. 
In addition, a copyright page will be included in a separate section, detailing that permission 
was granted from the American Cancer Society to reprint the table. 
The copyright page that I need filled out is included as part of this fax. It will either need to 
be mailed to me since it requires a signature, or scanned into a document and emailed. If 
the table from the document requested is public domain, then no copyright form is needed. 
However, I still need confirmation stating the document and the table requested is public 
domain. Proper citation will still be given as previously mentioned. 
A final copy of the thesis will be shelved in the library at UNLV, as well as placed on 
microfilm. The thesis will not be sold, but may be referenced to in the future by other 
researchers. 
Thank you for your help regarding my thesis. If there is any other information needed, 
please feel free to contact me by any of the methods listed below. Also, if there is anything I 
can do to speed up the request process, please let me know that as well. Thank you again. 
Sincerely, 
Robert Etnire 
7 9 3 7 T E R R A C E R O C K W A Y # 1 0 1 
L A S V E G A S , N V 8 9 1 2 8 
P H O N E : 7 0 2 - 8 6 9 - 5 8 8 9 
E M A I L : R E 1 8 2 @ A O L . C O M 
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